Sage Journals: Discover world-class research

Abstract

Get full access to this article

View all access options for this article.

References

Obesity and overweight. Available: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight [Accessed 15 Oct 2021].

Lundgren JR , Janus

, Jensen

SBK

, . Healthy weight loss maintenance with exercise, liraglutide, or both combined. N Engl J Med 2021;384:1719–30.doi:10.1056/NEJMoa2028198

http://www.ncbi.nlm.nih.gov/pubmed/33951361

Bessesen

, Van Gaal

. Progress and challenges in anti-obesity pharmacotherapy. Lancet Diabetes Endocrinol 2018;6:237–48.doi:10.1016/S2213-8587(17)30236-X

http://www.ncbi.nlm.nih.gov/pubmed/28919062

High dose Semaglutide for weight loss and cardiometabolic risk reduction in Overweight/Obesity. American College of cardiology. Available: https://www.acc.org/latest-in-cardiology/articles/2021/07/21/14/06/http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2021%2f07%2f21%2f14%2f06%2fhigh-dose-semaglutide-for-weight-loss-and-cardiometabolic-risk-reduction [Accessed 31 Oct 2021].

Kushner

, Calanna

, Davies

, . Semaglutide 2.4 mg for the treatment of obesity: key elements of the STEP trials 1 to 5. Obesity 2020;28:1050–61.doi:10.1002/oby.22794

Wilding

JPH

, Batterham

, Calanna

, . Once-Weekly Semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002.doi:10.1056/NEJMoa2032183

http://www.ncbi.nlm.nih.gov/pubmed/33567185

Davies

, Færch

, Jeppesen

, . Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (step 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021;397:971–84.doi:10.1016/S0140-6736(21)00213-0

http://www.ncbi.nlm.nih.gov/pubmed/33667417

Wadden

, Bailey

, Billings

, . Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity. JAMA 2021;325:1403–11.doi:10.1001/jama.2021.1831

Rubino

, Abrahamsson

, Davies

, . Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity. JAMA 2021;325:1414–12.doi:10.1001/jama.2021.3224

10.

Singh

, Krauthamer

, Bjalme-Evans

. Wegovy (semaglutide): a new weight loss drug for chronic weight management. J Investig Med 2022;70:5–13.doi:10.1136/jim-2021-001952

http://www.ncbi.nlm.nih.gov/pubmed/34706925

11.

Lingvay

, Hansen

, Macura

, . Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. BMJ Open Diabetes Res Care 2020;8:e001706. doi:10.1136/bmjdrc-2020-001706

http://www.ncbi.nlm.nih.gov/pubmed/33115821

12.

Blundell

, Finlayson

, Axelsen

, . Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19:1242–51.doi:10.1111/dom.12932

http://www.ncbi.nlm.nih.gov/pubmed/28266779

Semaglutide 2.4 Mg: The Latest GLP-1RA Approved for Obesity

Abstract

Get full access to this article

References